This is a Trial of MG1-E6E7 With Ad-E6E7 and Atezolizumab in Patients With HPV Associated Cancers

Key Inclusion Criteria:

- Histologically or cytologically confirmed recurrent or metastatic HPV associated tumor
(cervical, oropharyngeal, vulvar, vaginal, anal, or penile) with documented disease
progression.

- Arm 1, Phase 1 dose escalation: Cervical, HPV+ oropharyngeal, vulvar, vaginal, anal,
or penile

- Arm 1, Cohort A: Cervical cancer

- Arm 1, Cohort B: HPV+ Oropharyngeal cancer

- Arm 2 Phase 1 dose escalation and Cohort C: Cervical, oropharyngeal, vulvar, vaginal,
anal, or penile

- Failed, refused or intolerant to systemic therapy

- Measurable disease based on RECIST 1.1

- At least one tumor mass amenable to core needle biopsy

- Arm 2 only: At least one tumor judged as being safely injectable

- ECOG performance status 0 or 1

- Demonstrate adequate organ function

- Additional Inclusion criteria exist

Key Exclusion Criteria:

- Prior systemic therapy within 4 weeks.

- Patients receiving prior XRT must have recovered from any acute toxicity.

- Currently receiving/received experimental therapy within 4 weeks.

- Prior treatment with any HPV vaccine therapy for cancer.

- Requires use of anti-platelet or anti-coagulant therapy that cannot be safely
suspended for per protocol biopsies or intra-tumoral injections.

- Known active CNS metastases and/or carcinomatous meningitis.

- Clinically significant tumor invasion/ rapidly accumulating ascites, pericardial or
pleural effusions.

- Active infection requiring systemic therapy.

- Active autoimmune disease that has required systemic therapy in the past 2 years.

- Conditions likely to have resulted in splenic dysfunction.

- Known HIV/AIDS, active HBV or HCV infection.

- Received prior treatment with vesicular stomatitis (VSV) viral vector.

- Received immunosuppressive medication within 4 weeks. (>10mg/day prednisone)

- ≥ Grade 2 dyspnea and/or require supplemental oxygen

- Known intolerance to anti-PD-1 or anti-PD-L1 antibody therapy

- Additional Exclusion criteria exist

Exclusion Criteria Household Contacts:

- Patients with household contacts meeting any of the following criteria are ineligible
for study entry unless alternate living arrangements can be made, while under contact
precautions.

- Women who are pregnant or nursing an infant

- Children < 1 year old

- Individuals who are severely immunocompromised

- Contact precautions are from initial treatment with MG1-E6E7 to 7 days after the last
dose of MG1-E6E7